Logo.jpg
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 06, 2023 09:30 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Logo.jpg
GT Biopharma Reports Third Quarter 2023 Financial Results
November 01, 2023 09:00 ET | GT Biopharma, Inc.
IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia...
Logo.jpg
GT Biopharma Reports Second Quarter 2023 Financial Results
August 07, 2023 09:00 ET | GT Biopharma, Inc.
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical...
Logo.jpg
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023
August 03, 2023 13:25 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
Logo.jpg
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 17:00 ET | GT Biopharma, Inc.
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...
Logo.jpg
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 04, 2023 09:05 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
Logo.jpg
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 17:00 ET | GT Biopharma, Inc.
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium...
Logo.jpg
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
February 02, 2023 09:46 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Logo.jpg
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 30, 2022 08:00 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Logo.jpg
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
December 14, 2022 07:30 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...